Table 3.
Multivariate analysis using cox-proportional hazard model to analyze impact of demographic and clinical parameters on progression-free survival according to generation of EGFR TKI received
| Variable | 1st/2nd Gen, HR | 1st/2nd Gen, 95% CI | 3rd Gen, HR | 3rd Gen, 95% CI |
|---|---|---|---|---|
| Sex | ||||
| Female | Reference | Reference | ||
| Male | 0.3762 | 0.068 to 1.553 | 2.515 | 1.147 to 5.513 |
| Ethnicity | ||||
| Asian/Pacific Islander | Reference | Reference | ||
| Other | 2.462 | 0.840 to 7.863 | 1.315 | 0.566 to 2.998 |
| Smoking status | ||||
| Never smoker | Reference | Reference | ||
| Ever smoker | 15.12 | 2.467 to 118.1 | 1.006 | 0.435 to 2.173 |
| Tumor histology | ||||
| Adenocarcinoma | Reference | Reference | ||
| Other | 2.752 | 0.248 to 22.64 | 4.271 | 0.875 to 15.90 |
| Brain mets | ||||
| No | Reference | Reference | ||
| Yes | 5.940 | 2.082 to 18.00 | 1.379 | 0.652 to 2.789 |
| BMI | 0.896 | 0.796 to 1.00 | 0.969 | 0.895 to 1.039 |
| Age at treatment initiation | 0.981 | 0.943 to 1.019 | 1.024 | 0.996 to 1.055 |
| Albumin | ||||
| ≥ 3.2 | Reference | Reference | ||
| < 3.2 | 0.673 | 0.115 to 2.938 | 0.971 | 0.139 to 4.0930 |
| NLR | ||||
| < 5 | Reference | Reference | ||
| ≥ 5 | 0.653 | 0.198 to 2.021 | 0.631 | 0.309 to 1.255 |
| PLR | ||||
| < 180 | Reference | Reference | ||
| ≥ 180 | 1.789 | 0.521 to 6.010 | 1.598 | 0.634 to 3.981 |